Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001731122-26-001166
Filing Date
2026-08-28
Accepted
2026-08-28 16:26:49
Documents
48
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q e7885_10-q.htm   iXBRL 10-Q 736052
2 EXHIBIT 31.1 e7885_ex31-1.htm EX-31.1 7887
3 EXHIBIT 31.2 e7885_ex31-2.htm EX-31.2 7916
4 EXHIBIT 32.1 e7885_ex32-1.htm EX-32.1 5835
5 GRAPHIC image_001.jpg GRAPHIC 25369
6 GRAPHIC image_002.jpg GRAPHIC 30380
  Complete submission text file 0001731122-26-001166.txt   3647095

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE avxl-20260331.xsd EX-101.SCH 29583
8 XBRL CALCULATION FILE avxl-20260331_cal.xml EX-101.CAL 28433
9 XBRL DEFINITION FILE avxl-20260331_def.xml EX-101.DEF 82102
10 XBRL LABEL FILE avxl-20260331_lab.xml EX-101.LAB 251369
11 XBRL PRESENTATION FILE avxl-20260331_pre.xml EX-101.PRE 194727
51 EXTRACTED XBRL INSTANCE DOCUMENT e7885_10-q_htm.xml XML 479158
Mailing Address 630 5TH AVENUE 20TH FLOOR NEW YORK NY 10111
Business Address 630 5TH AVENUE 20TH FLOOR NEW YORK NY 10111 844-689-3939
ANAVEX LIFE SCIENCES CORP. (Filer) CIK: 0001314052 (see all company filings)

EIN.: 980608404 | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-37606 | Film No.: 261340644
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)